Recce Pharmaceuticals 将来の成長

Future 基準チェック /06

Recce Pharmaceuticalsの収益は年間13.1%で減少すると予測されていますが、年間利益は年間18.3%で増加すると予想されています。EPS は年間30.2%で増加すると予想されています。

主要情報

18.3%

収益成長率

30.2%

EPS成長率

Pharmaceuticals 収益成長	36.9%
収益成長率	-13.1%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	13 Dec 2024

今後の成長に関する最新情報

更新なし

Recent updates

We Think Shareholders Are Less Likely To Approve A Pay Rise For Recce Pharmaceuticals Ltd's (ASX:RCE) CEO For Now

Nov 01

Here's Why We're Watching Recce Pharmaceuticals' (ASX:RCE) Cash Burn Situation

Feb 13

We're Hopeful That Recce Pharmaceuticals (ASX:RCE) Will Use Its Cash Wisely

Jul 28

Recce Pharmaceuticals (ASX:RCE) Is In A Good Position To Deliver On Growth Plans

Dec 07

We're Hopeful That Recce Pharmaceuticals (ASX:RCE) Will Use Its Cash Wisely

Aug 03

Recce Pharmaceuticals (ASX:RCE) Is In A Good Position To Deliver On Growth Plans

Mar 08

Need To Know: Recce Pharmaceuticals Ltd (ASX:RCE) Insiders Have Been Selling Shares

Feb 01

Could The Recce Pharmaceuticals Ltd (ASX:RCE) Ownership Structure Tell Us Something Useful?

Dec 09

業績と収益の成長予測

ASX:RCE - アナリストの将来予測と過去の財務データ ( )AUD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
6/30/2027	3	-12	-11	-11	1
6/30/2026	5	-10	-44	-11	2
6/30/2025	8	-18	-10	-10	2
6/30/2024	5	-18	-13	-13	N/A
3/31/2024	6	-14	-11	-11	N/A
12/31/2023	7	-11	-9	-9	N/A
9/30/2023	6	-12	-11	-11	N/A
6/30/2023	4	-13	-13	-13	N/A
3/31/2023	4	-14	-14	-14	N/A
12/31/2022	3	-15	-15	-14	N/A
9/30/2022	3	-13	-12	-12	N/A
6/30/2022	3	-11	-9	-9	N/A
3/31/2022	2	-10	-8	-8	N/A
12/31/2021	1	-8	-7	-7	N/A
9/30/2021	1	-11	-8	-8	N/A
6/30/2021	2	-14	-8	-8	N/A
3/31/2021	1	-13	-8	-8	N/A
12/31/2020	1	-13	-8	-8	N/A
9/30/2020	1	-9	-6	-6	N/A
6/30/2020	1	-4	-4	-4	N/A
3/31/2020	1	-4	-3	-3	N/A
12/31/2019	1	-3	-3	-3	N/A
9/30/2019	1	-3	-3	-3	N/A
6/30/2019	1	-3	-3	-3	N/A
3/31/2019	1	-2	-2	-2	N/A
12/31/2018	2	-2	-2	-2	N/A
9/30/2018	1	-2	-2	-2	N/A
6/30/2018	1	-2	-2	-2	N/A
3/31/2018	1	-2	N/A	-2	N/A
12/31/2017	1	-3	N/A	-2	N/A
9/30/2017	0	-3	N/A	-2	N/A
6/30/2017	0	-3	N/A	-2	N/A
3/31/2017	0	-3	N/A	-2	N/A
12/31/2016	0	-2	N/A	-2	N/A
9/30/2016	0	-4	N/A	-2	N/A
6/30/2016	0	-5	N/A	-2	N/A
3/31/2016	0	-5	N/A	-1	N/A
12/31/2015	0	-4	N/A	-1	N/A
9/30/2015	0	-2	N/A	0	N/A
6/30/2015	0	0	N/A	0	N/A
6/30/2014	0	0	N/A	N/A	N/A

アナリストによる今後の成長予測

収入対貯蓄率: RCE今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: RCE今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: RCE今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: RCEの収益は今後 3 年間で減少すると予想されています (年間-13.1% )。

高い収益成長: RCEの収益は今後 3 年間で減少すると予測されています (年間-13.1% )。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: RCEの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2024/12/22 06:52
終値	2024/12/20 00:00
収益	2024/06/30
年間収益	2024/06/30

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を例とし、非米国証券については同等の規制書式と情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Recce Pharmaceuticals Ltd 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。2

アナリスト	機関
Pooya Hemami	Edison Investment Research
Chris Kallos	MST Financial Services Pty Limited

Recce Pharmaceuticals 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Recent updates

Recce Pharmaceuticals Ltd Receives Approval from Indonesia's Drug and Food Authority for Registrational Phase 3 Trial of Recce®? 327 Topical Gel in Diabetic Foot Infections

Recce Pharmaceuticals Ltd Receives Ethics Approval in Indonesia to Commence Registrational Phase 3 Trial of Recce®?327 Topical Gel in Diabetic Foot Infections

Recce Pharmaceuticals Advances Patient Dosing to Final Stages in Phase II Trial for Acute Bacterial Skin and Skin Structure Infections

Recce Pharmaceuticals Announces Recruitment Passes Halfway in Phase II Trial for Acute Bacterial Skin and Skin Structure Infections

Recce Pharmaceuticals Ltd, Annual General Meeting, Nov 06, 2024

New major risk - Revenue and earnings growth

Recce Pharmaceuticals Announces Positive Preclinical Efficacy Data Against WHO Priority Pathogen Acinetobacter Baumannii

Recce Pharmaceuticals Ltd has filed a Follow-on Equity Offering in the amount of AUD 2 million.

Recce Pharmaceuticals Reports Positive Data from Phase I/Ii Urinary Tract Infection (Uti) / Urosepsis Rapid Infusion Trial of Recce® 327

Recce Pharmaceuticals Ltd. Receives Ethics Approval to Broaden RECCE 327 Gel Trials Across All Topical Bacterial Skin Infections

Recce Pharmaceuticals Announces Addition of RECCE® 327 to the World Health Organization’S List of Antibacterial Products in Clinical Development

Recce Pharmaceuticals Ltd Doses First Participants in Next Cohort of Phase I/II Urinary Tract Infections and Urosepsis Rapid Infusion Clinical Trial

Recce Pharmaceuticals Reports Positive Preclinical Data of Recce® 327 in Lung Infection Pilot Study

Recce Pharmaceuticals Ltd Receives New Patent in China for RECCE Anti-Infectives from China National Intellectual Property Administration

New major risk - Revenue and earnings growth

Recce Pharmaceuticals Ltd. Announces Safety Committee Approves High Dose of 4,000mg in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis

Recce Pharmaceuticals Ltd. Completes 5,000 RECCE 327 Doses Week Under Good Manufacturing Practice

Recce Pharmaceuticals Ltd Receives New Patent in Israel for Recce Anti-Infectives

New major risk - Revenue and earnings growth

Recce Pharmaceuticals Completes Dosing Cohort in Phase I/II Trial of Recce® 327 for Urinary Tract Infections and Urosepsis

Recce Pharmaceuticals Ltd Doses Next Cohort in Phase I/II Trial of RECCE 327 for Urinary Tract Infections and Urosepsis

Recce Pharmaceuticals Reports Positive Phase I/II Trial Results of RECCE 327 for the Treatment of Diabetic Foot Infections

Recce Pharmaceuticals Receives Ausindustry Advanced Overseas Finding for Synthetic Anti-Infective Research & Development Program

Recce Pharmaceuticals Ltd Reports Positive Preclinical Data of RECCE 327 Against Gonorrhoeae

Recce Pharmaceuticals Limited Announces Canadian Patent Granted for Recce® Anti-Infectives

Recce Pharmaceuticals Ltd Completes Dosing First Subjects at 15-Minute Infusion Rate in a Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis

We Think Shareholders Are Less Likely To Approve A Pay Rise For Recce Pharmaceuticals Ltd's (ASX:RCE) CEO For Now

Recce Pharmaceuticals Ltd Announces Safety Committee Approves Faster Infusion Rate in Phase I/Ii Trial of Recce® 327 for Urinary Tract Infections and Urosepsis

Recce Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 3.022261 million.

Recce Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 3.022261 million.

Recce Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 2.715261 million.

Recce Pharmaceuticals Completes Dosing in Phase I/II Clinical Trial of Recce® 327 for Urinary Tract Infections

Recce Pharmaceuticals Ltd, Annual General Meeting, Nov 08, 2023

New minor risk - Shareholder dilution

Recce Pharmaceuticals Ltd Provides Additional Positive Update on Patients Treated Under "Special Access Scheme"

Recce Pharmaceuticals Ltd Announces Safety Committee Approves Next Dose of Recce®? 327 At 3,000Mg in Phase I/Iiuti/Urosepsis Rapid Infusion Clinical Trial

New minor risk - Financial data availability

Recce Pharmaceuticals Ltd Doses Patients in Phase I/II Clinical Trial of Recce 327 for Diabetic Foot Infections

Recce Pharmaceuticals Ltd. Completes Stage 1 Data Analysis of Phase I/II Clinical Trial for the Treatment of Burn Wound Infections

Recce Pharmaceuticals Ltd Provides Positive Update on Patients Treated with RECCE®? 327 Under "Special Access Scheme"

Recce Pharmaceuticals Completes First Cohort Dosing of Phase l/ll UTI Rapid Infusion Clinical Trial at Scientia Clinical Research

Recce Pharmaceuticals Achieves Positive Phase I Clinical Trial Data of RECCE(R) 327 as an Intravenous Infusion Formulation

Recce Pharmaceuticals Limited Announces First Cohort Dosed in Recce®? 327 Rapid Infusion Phase I/II Urinary Tract Infection (UTI) Clinical Trial

CEO, MD & Executive Director recently bought AU$308k worth of stock

Here's Why We're Watching Recce Pharmaceuticals' (ASX:RCE) Cash Burn Situation

Recce Pharmaceuticals to Be Granted Anti-Viral Patent in Australia for RECCE® Anti-Infectives

Recce Pharmaceuticals Limited Announces Australian Patent Office Issued Notification of Intent to Grant Recce's Patent Family 3

Recce Pharmaceuticals Ltd Receives Ethics Approval to Start Phase 1/2 Study Evaluating RECCE(R) 327 in Patients with Diabetic Foot Infections

Recce Pharmaceuticals Ltd Receives Ethics Approval to Start Phase I/II Diabetic Foot Ulcer Study

Less than half of directors are independent

Recce Pharmaceuticals Ltd Provides RECCE 327 SARS-CoV-2 Study Update

Recce Pharmaceuticals Ltd Provides RECCE 327 SARS-CoV-2 Study Update

Recce Pharmaceuticals Announces Expansion and Acceleration of Clinical Programs

Recce Pharmaceuticals Ltd, Annual General Meeting, Nov 14, 2022

Recce Pharmaceuticals Appoints Alistair McKeough to Its Board of Directors and Maggie Niewidok as Company Secretary

Recce Announces Management Changes

Recce Pharmaceuticals Ltd Reports Positive Safety Data from Seventh Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327

We're Hopeful That Recce Pharmaceuticals (ASX:RCE) Will Use Its Cash Wisely

Recce Pharmaceuticals Ltd announces Positive Safety Data from Fifth Cohort of Phase I Clinical Trial of RECCE 327 and Initiates Sixth Cohort At 4,000Mg

Less than half of directors are independent

Recce Pharmaceuticals Ltd Announces Anti-Viral Patent Granted in Hong Kong

Recce Pharmaceuticals Ltd Announces Safety Committee Clears Next Dose in Phase I Study of Recce® 327

Recce Pharmaceuticals Ltd Announces Positive Safety Data from Second Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327

Recce Pharmaceuticals Ltd Announces Patients to be Dosed in a Phase I Intravenous Clinical Trial of RECCE® 327

Recce Pharmaceuticals (ASX:RCE) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Recce Pharmaceuticals (ASX:RCE) Will Use Its Cash Wisely

Anti-Viral Patent Grants in USA for Recce Pharmaceuticals Ltd's RECCE Anti-Infectives

Chinese Patent Office Grants Anti-Viral Patent to Recce Pharmaceuticals Ltd

Board Member recently sold AU$178k worth of stock

Recce Pharmaceuticals Ltd. Provides Recce Clinical Pipeline Update

Recce Pharmaceuticals Ltd Announces Positive Results of Lead Compound RECCE® 327

Recce Pharmaceuticals Ltd Announces Further Results for its Synthetic Anti-Infective R327

Recce Pharmaceuticals Ltd Announces Positive Data on RECCE 327 Against All Six ESKAPE Pathogens

Recce Pharmaceuticals Ltd Announces Lead Compound Recce 327 Added to the Pew Charitable Trusts' Annual List of Non-Traditional Products

Recce Pharmaceuticals (ASX:RCE) Is In A Good Position To Deliver On Growth Plans